Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : US1101221083
Share Class Description:
BMY: Ordinary SharesTotal Employee Number:
32,500Compare
Compare
Traded in other countries / regions
BMY.USA0R1F.UKBMY.ArgentinaBRM.GermanyBMY.Mexico1BMY.ItalyBMY.PeruBMYS.AustriaBMYB34.BrazilBMY.Switzerland Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1952-06-23Description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 2.02 | |||||
Debt-to-EBITDA | 2.68 | |||||
Interest Coverage | 8 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.76 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.2 | |||||
3-Year EBITDA Growth Rate | -5.9 | |||||
3-Year EPS without NRI Growth Rate | -7.2 | |||||
3-Year FCF Growth Rate | 4.2 | |||||
3-Year Book Growth Rate | -15.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -3.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -4.82 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.89 | |||||
9-Day RSI | 77.02 | |||||
14-Day RSI | 71.01 | |||||
3-1 Month Momentum % | -4.9 | |||||
6-1 Month Momentum % | 4.67 | |||||
12-1 Month Momentum % | 33.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.53 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 0.59 | |||||
Days Inventory | 68.02 | |||||
Days Sales Outstanding | 68.2 | |||||
Days Payable | 107.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.83 | |||||
Dividend Payout Ratio | 0.39 | |||||
3-Year Dividend Growth Rate | 4.4 | |||||
Forward Dividend Yield % | 3.86 | |||||
5-Year Yield-on-Cost % | 5.2 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 6.66 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.16 | |||||
Operating Margin % | 28.14 | |||||
Net Margin % | 18.87 | |||||
EBITDA Margin % | 34.19 | |||||
FCF Margin % | 23.26 | |||||
OCF Margin % | 25.99 | |||||
ROE % | 47.92 | |||||
ROA % | 10.18 | |||||
ROIC % | 14.07 | |||||
3-Year ROIIC % | -35.29 | |||||
ROC (Joel Greenblatt) % | 150.91 | |||||
ROCE % | 20.13 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.39 | |||||
Forward PE Ratio | 10.29 | |||||
PE Ratio without NRI | 10.03 | |||||
Shiller PE Ratio | 37.37 | |||||
Price-to-Owner-Earnings | 15.59 | |||||
PEG Ratio | 3.58 | |||||
PS Ratio | 2.71 | |||||
PB Ratio | 5.98 | |||||
Price-to-Free-Cash-Flow | 11.66 | |||||
Price-to-Operating-Cash-Flow | 10.43 | |||||
EV-to-EBIT | 12.27 | |||||
EV-to-Forward-EBIT | 10.56 | |||||
EV-to-EBITDA | 9.96 | |||||
EV-to-Forward-EBITDA | 9.33 | |||||
EV-to-Revenue | 3.4 | |||||
EV-to-Forward-Revenue | 3.51 | |||||
EV-to-FCF | 14.64 | |||||
Price-to-GF-Value | 1.17 | |||||
Price-to-Projected-FCF | 0.95 | |||||
Price-to-DCF (Earnings Based) | 0.81 | |||||
Price-to-DCF (FCF Based) | 0.37 | |||||
Price-to-Median-PS-Value | 0.79 | |||||
Earnings Yield (Greenblatt) % | 8.15 | |||||
FCF Yield % | 8.58 | |||||
Forward Rate of Return (Yacktman) % | 7.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:BMY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bristol-Myers Squibb Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 49,187 | ||
| EPS (TTM) ($) | 4.54 | ||
| Beta | 0.1086 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 23.1 | ||
| 14-Day RSI | 71.01 | ||
| 14-Day ATR ($) | 1.676563 | ||
| 20-Day SMA ($) | 60.4435 | ||
| 12-1 Month Momentum % | 33.04 | ||
| 52-Week Range ($) | 42.52 - 65.658 | ||
| Shares Outstanding (Mil) | 2,042.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bristol-Myers Squibb Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 08:00 | In 90 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 89 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:15 | 63.10 (-1.21%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 63.10 (-1.21%) | ||
| USD 0.630000 Cash Dividend | 2026-07-02 | 56.44 (-2.05%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 14:00 | 55.57 (-2.78%) | ||
| Guidance call for 2026 | 2026-05-14 11:40 | 56.39 (+0.88%) | ||
| General meeting for 2026 | 2026-05-05 10:00 | 57.38 (-0.47%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:00 | 57.59 (-0.10%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 57.59 (-0.10%) |
Show
Entries
Bristol-Myers Squibb Co Frequently Asked Questions
What is Bristol-Myers Squibb Co(BMY)'s stock price today?
The current price of BMY is $65.31. The 52 week high of BMY is $65.66 and 52 week low is $42.52.
When is next earnings date of Bristol-Myers Squibb Co(BMY)?
The next earnings date of Bristol-Myers Squibb Co(BMY) is 2026-10-29.
Does Bristol-Myers Squibb Co(BMY) pay dividends? If so, how much?
The Dividend Yield %  of Bristol-Myers Squibb Co(BMY) is 3.83% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(BMY) was 2.1. The lowest was 0.27. And the median was 0.38. The  Forward Dividend Yield % of Bristol-Myers Squibb Co(BMY) is 3.86%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:BMY
No articles.
Press Release
Articles on Bristol-Myers Squibb Co
Headlines
See More- 1
Jul 31, 2026
SA analyst upgrades/downgrades: AAPL, CVNA, BMY, ORCL
Seeking Alpha • 2:24pm
Replimune surges on positive AdCom vote on lead drug
Seeking Alpha • 10:00pm
Jul 30, 2026
BMS granted FDA review for label expansion of Merck-partnered anemia therapy
Seeking Alpha • 12:26pm
Stocks to watch on Thursday: LRCX, CRWV, BMY and more
Seeking Alpha • 9:07am
Bristol-Myers Squibb in charts: Q2 revenue from Eliquis, Yervoy, and Orencia rises Y/Y; Sprycel, Opdivo, and Pomalyst/Imnovid falls
Seeking Alpha • 7:31am
Earnings Snapshot: BMY boosts outlook; Eliquis demand growth tempered by generic competition in legacy portfolio
Seeking Alpha • 6:14am
Jul 22, 2026
Trump outlines plans for up to 200% tariffs on generic drug imports starting in 2028
Seeking Alpha • 11:41pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers